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Background: Recent studies have demonstrated that DNA polymorphisms in the solute carrier family 30 member 8
(SLC30A8) gene confer the risk susceptibility to type 2 diabetes (T2D). The present study aimed to analyze DNA
methylation levels of this gene in T2D and diabetic nephropathy (DN).
Results: We confirmed the genetic association study of SLC30A8 in 992 Malay subjects with normal glucose
tolerance and T2D patients with and without DN. Genotyping was conducted with TaqMan allelic discrimination.
SNP rs11558471(A/G) in the SLC30A8 gene was strongly associated with T2D (P = 0.002, OR = 1.334, 95% CI = 1.110
to 1.602) and moderately associated with DN (P = 0.041, OR = 1.399, 95% CI = 1.013 to 1.932). We further performed
DNA methylation analysis of six CpG sites in the SLC30A8 gene promoter with bisulfite pyrosequencing protocol.
The average DNA methylation levels of the SLC30A8 gene in all Malay subjects were at approximately 81.4%. DNA
methylation levels of the SLC30A8 gene in T2D patients were higher compared to non-diabetic subjects (82.9% vs.
80.1%, P = 0.014). But no significant difference of DNA methylation levels of the SLC30A8 gene between T2D patients
with and without DN was observed.
Conclusion: The present study thus provides the first evidence that increased DNA methylation of the SLC30A8
gene promoter is associated with T2D but not DN in a Malay population.
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The solute carrier family 30 member 8 (SLC30A8) gene is
encoded for a zinc efflux transporter and highly expressed
in the pancreas, particularly in alpha, beta, and PP cells of
the islets of Langerhans. Functionally, this transporter is
essential for zinc flux into beta-cell insulin-secretory gran-
ules and the subsequent crystallization of hexameric insu-
lin [1]. Pathological studies have demonstrated that the
SLC30A8 gene expression levels are downregulated in pan-
creatic islets of diabetic mice [2]. The downregulation of
the SLC30A8 gene expression results in the reduction of
insulin content and glucose-inducible insulin secretion [3].* Correspondence: harvest.gu@ki.se
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unless otherwise stated.Genome-wide association studies (GWASs) have iden-
tified a number of susceptibility variants for type 2 dia-
betes (T2D). The common alleles of single nucleotide
polymorphisms (SNPs), rs13266634(C/T, Arg276Trp),
and rs11558471(A/G) in the SLC30A8 gene are found to
confer the risk susceptibility in T2D [4-9]. The genes in-
cluding SLC30A8 identified by GWAS, however, can
only explain approximately 10% of the overall heritable
risk of T2D, which challenges our expectations to trans-
late genetic information into clinical practice [10-12].
The missing information on heritability in T2D includes
the impact of rare variants and epigenetic factors. The
latter is involved in the complex interplay between genes
and the environment [13-15]. To further understand the
genetic effects of SLC30A8, Flannick et al. have recently
conducted a mutation screening study for rare variants
in the gene (the minor allele frequency is less 1%) andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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may protect against T2D [16].
Epigenetic factors mainly including DNA methylation
changes have been considered to be involved in the
pathogenesis of T2D [13-15]. The methylation of the 5′-
carbon of cytosine, often in a gene promoter, is a form
of epigenetic modification that does not affect the pri-
mary DNA sequences but affects secondary interactions
that play a critical role in the regulation of gene expres-
sion [17,18]. DNA methylation levels are commonly ana-
lyzed at clusters of CpG methylation sites in the gene
promoter and used for indication of epigenetic effects.
We have recently reported that DNA methylation changes
of the insulin-like growth factor 1 (IGF1) and its binding
proteins (IGFBP1 and IGFBP7) are associated with T2D
[19-22]. But whether the SLC30A8 gene is subject to epi-
genetic effects in T2D is unknown.
Malaysia is a country with a high prevalence of T2D at
14.9% for adults aged 30 years and above according to the
latest National Health and Morbidity Surveys in 2006
[23]. Moreover, diabetic nephropathy (DN) is the most
common cause of end-stage renal disease (ESRD). In this
country, DN contributes to 57% of patients with T2D
[24-26]. We have currently collected a cohort of Malay
subjects including normal glucose tolerance (NGT) and
T2D patients with and without DN for genetic studies. In
the present study, we conducted genetic association study
and further analyzed DNA methylation alteration of the
SLC30A8 gene in this Malay population. The results may
provide useful information to evaluate the genetic and epi-
genetic effects of the SCL30A8 gene in T2D and DN.Table 1 Clinical parameters of Malay subjects in genetic asso
Group NGT T2Da
N (men/women) 476 (224/252) 516 (260/256)
Age (years) 42 ± 15 56 ± 10
Diabetes duration (years) - 14 ± 8
BMI (kg/m2) 26 ± 7.0 28 ± 5
SBP (mm Hg) 127 ± 19 144 ± 25
DBP (mm Hg) 80 ± 11 81 ± 12
FPG (mmol/l) 4.87 ± 1.02 5.0 ± 1.22
HbA1c (%) 5.4 ± 0.48 8.1 ± 2.17
Serum creatinine (μmol/l) 67.8 ± 33.7 122.3 ± 114.4
Urine creatinine (mmol/l) 12.3 ± 7.4 10.0 ± 6.8
ACR (mg/mmol) 3.32 ± 16.1 57.3 ± 175.4
eGFR (ml/min/1.73 m2) 112.9 ± 45.2 71.4 ± 38.2
Data are expressed as means ± SD.
NGT normal glucose tolerance, T2D type 2 diabetes, DN diabetic nephropathy, BMI
FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, ACR albumin creatinin
aThe patients with microalbuminuria were included.
bP values were from tests of NGT vs. all T2D.
cP values were from tests of T2D without DN vs. T2D with DN.Results
Association of SLC30A8 genetic polymorphisms with T2D
and DN
A total of 992 Malay subjects including NGT subjects
(n = 476) and T2D patients with or without DN (516)
were included in the genotyping experiments. Clinical
parameters in all Malay subjects selected for genetic as-
sociation study are summarized in Table 1.
The SLC30A8 gene is located on chromosome
8q24.11. Both SNPs rs13266634(C/T) and rs11558471
(A/G) reside within exon 9 of the gene (Figure 1). The
first SNP is non-synonymous, in which the amino acid
arginine is changed to tryptophan, while the second one
is located at 3′-UTR of SLC30A8. We genotyped these
two SNPs in the Malay subjects with NGT and T2D, and
data showed the genotype distributions of these two
SNPs in Hardy-Weinberg equilibrium (HWE). Figure 2
illustrates that the frequencies of the major alleles in
both SNPs , that is, allele C of rs13266634(C/T) and A
of rs11558471(A/G) were increased from NGT to T2D
without DN and to T2D with DN. Analyses for single
marker association indicated that the A allele of
rs11558471(A/G) was strongly associated with T2D (the
A allele frequencies between NGT and all T2D were
0.552 vs. 0.620, P = 0.002, OR = 1.334, 95% CI = 1.110 to
1.602) and moderately associated with DN (T2D without
and with DN, 0.593 vs. 0.671, P = 0.041, OR = 1.399, 95%
CI = 1.013 to 1.932). The association of SNP rs13266634
(C/T) with T2D and DN was not significant (P = 0.053,
OR = 1.200, 95% CI = 0.997 to 1.443; and P = 0.098,
OR = 1.313, 95% CI = 0.950 to 1.815). Information ofciation study
T2D-DN T2D + DN P valuesb/c
239 (103/136) 124 (66/58)
55 ± 10 57 ± 10 <0.001/NS
13 ± 8 14 ± 7 -/NS
29 ± 5 27 ± 5 <0.001/0.059
139 ± 22 155 ± 31 <0.001/0.001
80 ± 12 82 ± 13 NS/NS
4.76 ± 1.00 5.6 ± 1.05 0.028/0.035
7.6 ± 2.0 8.6 ± 2.4 <0.001/<0.001
91.0 ± 72.9 207.3 ± 178.7 <0.001/<0.001
11.4 ± 6.2 5.0 ± 3.52 <0.001/<0.001
1.10 ± 0.819 249.2 ± 311.5 <0.001/<0.001
81.0 ± 29.9 48.3 ± 35.2 <0.001/<0.001
body mass index, SBP systolic blood pressure, DBP diastolic blood pressure,
e ratio, eGFR estimated glomerular filtration rate.
Figure 1 The CpG sites and single nucleotide polymorphisms in the SLC30A8 gene. The total length of the SLC30A8 gene is 226,442 bases.
RefSeq DNA sequence at NCBI GenBank: NC_000008.10, NC_018919.2, NT_008046.17.
Seman et al. Clinical Epigenetics  (2015) 7:30 Page 3 of 7genotype distribution and allele frequency comparison
analyses is summarized in Table 2.
Association of SLC30A8 DNA methylation with T2D and
DN
To avoid the error caused by ages, the NGT subjects and
T2D patients with age match were selected in DNA
methylation analyses (Table 3). In the promoter region
of the SLC30A8 gene, there is a cluster of neighboring
six CpG sites (Figure 1). We analyzed SLC30A8 DNA
methylation levels not only at each CpG site but also in
total means of all CpG sites. In this Malay cohort, the
average DNA methylation levels of all six CpG sites in the
SLC30A8 gene promoter were high (81.4%). Figure 3A
demonstrates the DNA methylation patterns of CpG sites
in the SLC30A8 gene promoter region among NGT sub-
jects and T2D patients with and without DN in the Malay
cohort. DNA methylation levels at five CpG sites of the
gene (except CpG2) in T2D patients were found to be
higher than those in NGT subjects, respectively (CpG1
83.9% vs. 81.9%, P = 0.031; CpG3 82.1% vs. 84.8%,
P = 0.003; CpG4 69.6% vs. 66.3%, P = 0.001; CpG5 86.2%
vs. 83.7%, P = 0.004; and CpG6 79.8% vs. 78.1%, P = 0.001)
(Figure 3A). Combining all six CpG sites together, totalFigure 2 Risk allele frequencies of the SLC30A8 polymorphisms in Ma
(A) and A of rs11558471(A/G) (B)) of the SLC30A8 polymorphisms in Malay
nephropathy. NGT normal glucose tolerance (dark bar), T2D-DN type 2 diab
2 diabetes with diabetic nephropathy (dark grey bar).mean values of SLC30A8 DNA methylation levels were
significantly increased in T2D patients compared with
NGT subjects (82.9%, 95% CI = 79.2% to 80.5% vs. 80.1%,
95% CI = 75.4% to 78.6%, P = 0.014) (Figure 3B). A linear
regression model was used to estimate the association be-
tween SLC30A8 DNA methylation levels in blood and
phenotypes of T2D, and no significant association was
found. Furthermore, the analyses of SLC30A8 DNA
methylation levels between the patients with and without
DN or according to the genotypes of SNPs rs13266634(C/
T) and rs11558471(A/G) were done and no significant dif-
ference of the levels was found.
Discussion
We have investigated DNA methylation levels of the
SLC30A8 gene in a Malay population. Our main findings
include: first, a cluster of CpG sites in the promoter re-
gion of the SLC30A8 gene is hypermethylated. Second,
increased DNA methylation levels of this gene are asso-
ciated with T2D but not with DN.
DNA methylation analysis can be performed in the
scales of global genome or specific gene region and in per-
ipheral blood with mixed cell types or specific tissues [27].
Dayeh et al. have recently performed human pancreaticlay subjects. Risk allele frequencies (allele C of rs13266634(C/T)
subjects with normal glucose tolerance, type 2 diabetes, and diabetic
etes without diabetic nephropathy (light grey bar), and T2D + DN type
Table 2 Association of the SLC30A8 genetic polymorphisms with type 2 diabetes and diabetic nephropathy in a Malay
population
SNP ID Group N Genotypes RAF P value Odds ratio
rs13266634 CC CT TT
NGT 438 153 202 83 0.580 0.053 1.200 (0.997 to 1.443)
All T2Da 506 208 215 83 0.620
T2D-DN 236 90 107 39 0.608 0.098 1.313 (0.950 to 1.815)
T2D + DN 123 59 47 17 0.670
rs11558471 AA AG GG
NGT 441 139 209 93 0.552 0.002 1.334 (1.110 to 1.602)
All T2Da 509 204 225 80 0.620
T2D-DN 237 87 107 43 0.593 0.041 1.399 (1.013 to 1.932)
T2D + DN 123 57 51 15 0.671
Tests were conducted with an additive model.
NGT normal glucose tolerance, T2D type 2 diabetes, DN diabetic nephropathy, RAF risk allele frequency.
aThe patients with microalbuminuria were included.
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omic regions of SNPs that are predicted to be associated
with T2D by GWAS [28]. In the SLC30A8 gene, three
CpG sites are located nearby SNP rs13266634. According
to the genotypes of this polymorphism, DNA methylation
changes at one of CpG sites are found to be significantly
different. However, the DNA methylation levels at this
CpG site are very low (<5%). Hall E et al. have further in-
vestigated the effects of palmitate on genome-wide mRNA
expression and DNA methylation patterns in human pan-
creatic islets. With the palmitate treatment, the SLC30A8
mRNA expression levels in human pancreatic islets are
found to be decreased. But whether DNA methylation
levels of this gene are affected by palmitate is unclear [29].Table 3 Clinical parameters of Malay subjects in epigenetic st
Group NGT T2Da
N (men/women) 27 (19/8) 161 (81/8
Age (years) 57 ± 9 56 ± 9
Diabetes duration (years) - 12 ± 7
BMI (kg/m2) 24 ± 4.0 28 ± 5
SBP (mm Hg) 132 ± 18 139 ± 24
DBP (mm Hg) 84 ± 14 80 ± 12
HbA1c (%) 5.7 ± 1.0 8.2 ± 2.0
Serum creatinine (μmol/l) 70.6 ± 17.1 126.4 ± 1
Urine creatinine (mmol/l) 12.3 ± 7.4 8.1 ± 6.8
ACR (mg/mmol) 0.86 ± 0.75 46.2 ± 12
eGFR (ml/min/1.73 m2) 102.8 ± 28.6 67.1 ± 28
SLC30A8 DNA methylation levels (95% CI) 80.1% (79.4 to 81.4) 82.9% (81
Data are expressed as means ± SD or 95% CI.
NGT normal glucose tolerance, T2D type 2 diabetes, DN diabetic nephropathy, BMI
FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, ACR albumin creatinin
aThe patients with microalbuminuria were included.
bP values were from tests of NGT vs. all T2D.
cP values were from tests of T2D without DN vs. T2D with DN.A recent report has indicated that both approaches of
whole-blood DNA methylation profiling and adipose
tissue-specific methylation analysis for study of epigenetic
changes are related to body mass index (BMI) and sug-
gested that the analysis of blood DNA methylation is
worthwhile and can reflect changes in relevant tissues for
a phenotype [30]. The present study is a clinical observa-
tion. Although we have no tissue sample of pancreatic is-
lets available for analysis, epigenetic study with blood
samples is clinically accessible. Our findings are unlikely
false positive because the average of DNA methylation of
the SLC30A8 gene is high. We have analyzed the SLC30A8
gene DNA methylation levels according to gender and
smoking factors; no significant change of the levels betweenudy
T2D-DN T2D + DN P valuesb/c
0) 109 (49/60) 43 (25/18)
55 ± 10 56 ± 10 NS/NS
11 ± 8 11 ± 7 -/NS
29 ± 5 27 ± 5 <0.001/NS
135 ± 20 150 ± 33 NS/NS
80 ± 12 83 ± 15 NS/NS
8.1 ± 2.0 8.6 ± 2.4 <0.001/NS
19.5 92.7 ± 72.9 215.8 ± 183.0 <0.005/<0.001
9.7 ± 6.2 5.0 ± 3.52 <0.001/<0.001
7.1 1.19 ± 0.84 195.1 ± 206.1 <0.001/<0.001
.0 76.5 ± 23.4 44.1 ± 26.0 <0.001/<0.001
.2 to 83.5) 82.7% (80.9 to 82.9) 83.6% (79.8 to 84.4) 0.014/0.632
body mass index, SBP systolic blood pressure, DBP diastolic blood pressure,
e ratio, eGFR estimated glomerular filtration rate.
Figure 3 DNA methylation changes of the SLC30A8 gene in Malay subjects. DNA methylation changes of the SLC30A8 gene in Malay
subjects with normal glucose tolerance, type 2 diabetes, and diabetic nephropathy. DNA methylation levels at five CpG sites of the gene (except
CpG2) in T2D patients were found to be higher than those in NGT subjects, respectively (A). Combining all six CpG sites together, total mean
values of SLC30A8 DNA methylation levels were significantly increased in T2D patients compared with NGT subjects (B). Data were means with
95% CI. NGT: normal glucose tolerance (dark bar); T2D-DN: type 2 diabetes without diabetic nephropathy (light grey bar) and T2D + DN: type 2
diabetes with diabetic nephropathy (dark grey bar).
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DNA methylation of the SLC30A8 gene in T2D is consist-
ent with the downregulation of the gene expression in pan-
creatic islets of diabetic animals as previously reported
[2,3]. Except age, gender, and smoking, the confounding
factor of ethnic group has been taken into our study.
Malaysian populations include Malays, Chinese, Indians,
and indigenous Sabahans and Sarawakians. To avoid the
error caused by this confounding factor, only Malay sub-
jects are selected for this study. However, the replication
study in other ethnic groups or populations may be neces-
sary to ascertain the SLC30A8 epigenetic effect in T2D.
In the recent years, several groups including ours have
begun to investigate the epigenetic effects in T2D. From
our studies [19-22] and other reports [27-30], we have
learnt that DNA methylation levels between non-diabetic
control subjects and T2D patients differ significantly but
the difference is small (often around 2%). The standard
deviation of detected DNA methylation values is generally
much less compared with the data from serum or plasma
protein analyses. Compared with an epigenetic study in
tumor, it may be more difficult to perform the same study
in T2D. There are a number of genes contributing to-
wards genetic and epigenetic effects to the disease, and
the contribution of each gene may be minor. In this case,
it is of importance to analyze the accumulating genetic
and epigenetic effects in T2D. Data from the present study
demonstrate that the SLC30A8 gene DNA methylation is
high and implicate that the association of increased
SLC30A8 DNA methylation levels with T2D should be in-
cluded into the accumulating analyses.Compared with genetic study of T2D, the progress of
genetic study of DN has been slowed down mainly due
to the difficulty of collection and characterization of sub-
jects [31]. Although genetic association studies of the
SLC30A8 genetic polymorphisms with T2D are well doc-
umented [4-9], no association of the genetic polymor-
phisms with DN has been reported. In the present study,
we have replicated the association of the SLC30A8 gen-
etic polymorphisms with T2D and also shown a moder-
ate association between SNP rs1155847(A/G) in the
gene and DN. The data provide the basic information
for further epigenetic analysis of the SLC30A8 gene in
the present study. However, the sample sizes of cases
(T2D patients with DN) and controls (T2D without DN)
are relatively small. Additional investigation with large
cohorts is necessary to confirm the association of the
SLC30A8 genetic polymorphisms with DN.
Conclusion
In conclusion, the present study provides the first evidence
that increased DNA methylation of the SLC30A8 gene is
associated with T2D but not DN in a Malay population.
Methods
Subjects
Malaysia is a country with multi-cultures and multi-ethnic
populations. We collected the subjects with NGT and
T2D from the collaborating centers all over Malaysia. The
ethnic distribution of our cohort was 67.6% Malays, 15.3%
Indians, 14.8% Chinese, and 2.3% indigenous Sabahans
and Sarawakians. To avoid the error caused by ethnic
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and Sarawakians were excluded in the present study. A
total of 950 Malay subjects with NGT (n = 441) and T2D
(509) were included in the genetic association study. The
patients with T2D were diagnosed based on medical his-
tory by the medical officer or by oral glucose tolerance test
(OGTT). All diagnoses were done based on World Health
Organization (WHO) criteria [32]. The patients with T2D
and normoalbuminuria (ACR <3.5 mg/mmol) were con-
sidered as control subjects without DN, while the patients
with macroalbuminuria (ACR ≥35 mg/mmol) and ESRD
who needed dialysis were included as the cases with DN.
The diagnoses of DN were based on urine albumin-to-
creatinine ratio (ACR) suggested by ADA [33]. There were
131 T2D patients with microalbuminuria (ACR 3.5 to
35 mg/mmol). Finally, 237 patients without DN and 123
patients with DN were included in the study. Clinical
characteristics in all Malay subjects selected for genetic as-
sociation study and epigenetic analysis are summarized in
Tables 1 and 3, respectively.
The informed consent was given from all subjects, and
the study was approved by the local ethical committees.
All subjects need to answer a questionnaire and under-
went a medical examination guided by the research staff.
Data and material transfer agreement from the Institute
for Medical Research, Malaysia to Karolinska Institutet,
Sweden was completed prior to the study.Genomic DNA extraction
Genomic DNA extraction was isolated from fresh periph-
eral blood samples using a DNeasy blood and tissue extrac-
tion kit according to the manufacturer’s protocol (Qiagen,
Hilden, Germany) and quantified using a spectrophotom-
etry (Biophotometer Plus, Eppendorf, Germany).SNP selection and genotyping
Based upon information from the recent genetic associ-
ation studies, two SNPs, that is, rs13266634(Arg276Trp
C/T) and rs11558471(A/G) in the SLC30A8 gene, were
selected for our study [4-9]. The first SNP is non-
synonymous, in which the amino acid arginine is chan-
ged to tryptophan, while the second one is a synonym-
ous SNP at the 3′-UTR. The SLC30A8 gene structure
and location of these two polymorphisms are shown in
Figure 1. Genotyping these two SNPs were done using
TaqMan SNP genotyping assays purchased from Applied
Biosystems (Applied Biosystems, Foster City, USA).
Genotyping experiments were performed in ABI 7300
sequence detector with a Taqman allelic discrimination
protocol (Applied Biosystems). DNA samples were dis-
tributed randomly across plates with cases and controls
for genotyping quality control. All PCR reactions were
run in 20 μl volumes using 10 to 20 ng genomic DNA.Millipore water was used as negative controls (blanks)
on each plate.
Bisulfite treatment and pyrosequencing
Epigenetic analysis was performed by bisulfite pyrosequenc-
ing, which is a sensitive and accurate protocol [34,35].
DNA was treated with sodium bisulfite using EpiTect Bisul-
fite kit (Qiagen) and cleanup of bisulfite-converted DNA
was done. PCR amplification was then carried out using
PyroMark CpG assay (Qiagen) and PyroMark Gold Q96
Reagent kits (Qiagen) in a PyroMark Q96 system (Biotage
AB, Uppsala Sweden). PyroMark PCR master mix includes
HotStarTaq DNA polymerase and optimized PyroMark re-
action buffer containing 3 mM MgCl2 and dNTPs, 10x
CoralLoad Concentrate, 5x Q-Solution, 25 mM MgCl2,
and RNase-free water. The PCR amplicon covers the se-
quence in human chromosome 8: 117962434 to 117962479
(version 37.56). There are four CpG sites in the SLC30A8
gene promoter region as indicated with the bold letter ‘C’
and recorded as CpG1-4 (Figure 1). Finally, methylation
levels of these CpG sites were detected by using the Pyro-
Mark Gold 96 Reagent kit (Qiagen) and a PyroMark Q96
ID pyrosequencing system (Biotage). The unmethylated
and unconverted DNA samples (Qiagen) were used for
control of conversion efficiency in bisulfite treatment and
accuracy in methylation analyses. PyroQ-CpG software
(Biotage) was used for methylation data analysis.
Statistical analyses
Allele frequency and genotype distribution of the studied
SNPs were tested for HWE using the χ2 statistic. For dif-
ference between NGT subjects and T2D patients, two
models were tested comparing either allele frequencies
in 2 × 2 contingency tables (dominant) or genotypes in
3 × 2 contingency tables (additive). Odd ratios (OD) and
95% confidence intervals (CI) were calculated to test the
relative risk for association. Statistical power for genetic
association study was calculated by using the software of
PowerSampleSize (PS version 2.1.31). Since the major al-
leles of the studied SLC30A8 polymorphisms were risk
for T2D, and their frequencies were high (55% to 67%),
the sample sizes of cases and controls included in our
studies were sufficient to detect an association with T2D
at 85% powers. But the power to detect the association
with DN is low (approximately 55%). Tests for comparison
of continuous variables between groups were assessed by
unpaired t-test or one-way ANOVA followed with Tukey’s
post hoc test. Data in non-normally distributed traits were
transformed to the natural logarithm for obtaining a
normal distribution before performing statistical analysis.
To estimate the association between SLC30A8 DNA
methylation levels in blood and phenotypes of T2D, the
linear regression model was used. Data were given as the
means ± SD. P value less than 0.05 was considered
Seman et al. Clinical Epigenetics  (2015) 7:30 Page 7 of 7significant. Statistical calculations were performed by using
PASW Statistic Base 18 (SPSS Inc, Chicago, IL, USA).
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